MCKESSON CORP
MCKNYSETrading Snapshot
- Day Range
- $850.08 β $868.11
- 52-Week Range
- $723.68 β $999.00
- Volume
- $3.73B
- Avg Volume
- $3.32B
- Shares Outstanding
- 117.1M
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $403.43B
- Last Q Revenue
- $105.38B
- P/E Ratio
- 22.8
- P/S Ratio
- 0.2x
- EPS (TTM)
- $38.69
- Dividend Yield
- 0.40%
- Dilution (1yr)
- β3.6%
Why Investors Own MCK
- βHigh-growth profile β revenue up -8.5% YoY with expanding US Equity exposure.
- βHealthy economics β 56% gross margin and 24% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MCKESSON CORP
MCKAbout MCKESSON CORP
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
MCKESSON CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MCK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MCKESSON CORP announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.